Avalo Therapeutics
AVTX
16 hedge funds and large institutions have $53.6M invested in Avalo Therapeutics in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
1,000% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 1
167% more funds holding
Funds holding: 6 → 16 (+10)
97% more capital inflows, than outflows
Capital inflows: $995K | Capital outflows: $506K
0.26% more ownership
Funds ownership: 63.97% → 64.23% (+0.26%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bridgeway Capital Management
Houston,
Texas
|
+$388K |
| 2 |
Virtu Financial
New York
|
+$263K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$90.4K |
| 4 |
Armistice Capital
New York
|
+$73.2K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$38.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NEA Management Company
Timonium,
Maryland
|
-$506K |
AVTX Hedge Fund Activity: Q4 2017 in Review
16 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q4 2017, worth a combined $53.6M — up 278% from $14.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new AVTX positions and 1 closed out — a net gain of 10 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $388K. The largest seller was NEA Management Company, exiting entirely with an estimated $506K sold.
- 16 institutional investors held Avalo Therapeutics (AVTX) as of Q4 2017, up from 6 in Q3 2017.
- Funds reported $53.6M of Avalo Therapeutics stock for Q4 2017, up 278% quarter-over-quarter.
- 11 funds opened new Avalo Therapeutics positions in Q4 2017 and 1 closed out, a net change of +10 holders.
- The largest Avalo Therapeutics buyer in Q4 2017 was Bridgeway Capital Management, an estimated $388K added.
- The largest Avalo Therapeutics seller in Q4 2017 was NEA Management Company, an estimated $506K sold.
Based on aggregated 13F filings for Q4 2017.